Precigen (PGEN) Change in Accured Expenses (2012 - 2026)
Precigen's (PGEN) quarterly Change in Accured Expenses came in at -$2.3 million in Q1 2026, down 288.7% year-on-year from $1.2 million in Q1 2025, and down 977.22% on a QoQ basis from $259000.0 in Q4 2025.
Precigen (PGEN) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Change in Accured Expenses data on file, last reported at -$2.3 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 288.7% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 24.18% decrease from a year earlier, with the FY2025 full-year figure at $6.9 million, up 118.41% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$2.3 million, down from $259000.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for PGEN reached as high as $5.4 million in Q3 2023 and fell as low as -$2.8 million in Q4 2023.
- Historically, Change in Accured Expenses has averaged $412176.5 across 5 years, with a median of -$126000.0 in 2024.
- Across the five-year window, Change in Accured Expenses sank 366.01% in 2022 and soared 1214.69% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at -$939000.0 in 2022, then slumped by 202.24% to -$2.8 million in 2023, then soared by 163.67% to $1.8 million in 2024, then slumped by 85.67% to $259000.0 in 2025, then sank by 977.22% to -$2.3 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.3 million in Q1 2026, $259000.0 in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Precigen | 2.00 Bn | 2.00 Bn | 20.69 Mn | -2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.27 Mn |
| Mar 31, 2026 | -2.27 Mn |
| Dec 31, 2025 | 259,000.00 |
| Dec 31, 2025 | 259,000.00 |
| Sep 30, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | -130,000.00 |
| Sep 30, 2024 | -130,000.00 |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | -126,000.00 |
| Mar 31, 2024 | -126,000.00 |
| Dec 31, 2023 | -2.84 Mn |
| Dec 31, 2023 | -2.84 Mn |